Q-omics provides the consensus-scored PRKDC profile across patient tissues and cancer cell-line models. PRKDC expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRKDC is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PRKDC protein abundance shows 31,555 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where PRKDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKDC survival associations across molecular data types. PRKDC RNA expression shows survival associations in the most cancer types (28), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKDC RNA expression–survival associations across cancer types. High PRKDC expression shows unfavorable associations in MESO, UVM, ACC, UCEC and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PRKDC RNA expression.
This table summarizes PRKDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRKDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKDC shows higher tumor expression in HNSC, COAD, BLCA, STAD, LIHC and LUAD. The HNSC box plot shows higher PRKDC RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with PRKDC in patient tissues and cancer cell lines. In patient samples, PRKDC shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
